Cigna: Pandemic Led to Fewer New Scripts, Better Adherence
April
26
In its 2020 Drug Trend Report, Cigna Corp. division Evernorth said total drug costs rose 4% for its commercial plans, including both utilization and unit costs. The COVID-19 pandemic led to an across-the-board decline in the percentage of new medication users as well as improved adherence among people taking medications for chronic conditions. Among the top 15 therapy classes ranked by per-member per-year spend for the commercial plans, inflammatory conditions remained the top of the list, at $241.34 PMPY average spending, followed by diabetes at $145.24.
SOURCE: Evernorth. Visit https://www.evernorth.com/drug-trend-report.
© 2024 MMIT
Meet Our Reporters
-
Lauren Flynn Kelly Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits
View Leslie Small's Profile -
Peter Johnson Reporter, Health Plan Weekly and Radar on Drug Benefits
View Peter Johnson's Profile -
Tim Casey Reporter, Health Plan Weekly and Radar on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jinghong Chen's Profile